Epix Pharmaceuticals

Nereid Therapeutics Appoints Michael Kauffman as CEO

Retrieved on: 
Monday, November 13, 2023
Epix Pharmaceuticals, Research, Organization, Johns Hopkins, Therapy, Onyx Pharmaceuticals, MGM+, Biotechnology, Hospital, Verastem Oncology, EMA, Patient, Doctor of Philosophy, Takeda Oncology, Conference, Harvard Medical School, Drug discovery, Cancer, CMO, ATP, Beth Israel Hospital, Massachusetts General Hospital, Coronavirus Scientific Advisory Board, Amgen, Pharmaceutical industry, Nereids, Biogen

BOSTON, Nov. 13, 2023 /PRNewswire/ -- Nereid Therapeutics, a biotechnology company that is discovering new disease treatments by applying pioneering research and technologies to biomolecular condensates, announced today that Michael Kauffman, M.D., Ph.D., has joined the company as President and Chief Executive Officer. Dr. Kauffman will also join the Nereid Board of Directors. Spiros Liras, Ph.D., a venture partner at Apple Tree Partners (ATP) who has been acting CEO of Nereid since the company was created by ATP in late 2020, will continue to serve on Nereid's Board of Directors and the company's Scientific Advisory Board.

Key Points: 
  • Dr. Kauffman will also join the Nereid Board of Directors.
  • "Michael brings to Nereid the right energy at the right time.
  • He currently chairs the boards of BiVictriX Therapeutics and Incendia Therapeutics and serves on the Boards of Verastem Oncology, Kezar Life Sciences, and Adicet Bio.
  • Dr. Kauffman and other members of the Nereid leadership team will be onsite for meetings at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-11, 2024, in San Francisco, CA.

Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla

Retrieved on: 
Wednesday, June 28, 2023
Acumen, ABOS, LLP, University, OncoMed, Doctor of Philosophy, AbbVie, Stanford University, Epix Pharmaceuticals, ABBV, CSC, Cancer, Record, ASX, Babson College, PwC, IMU, Takeda Oncology, Proteostasis, Kineta, Molecular biology, Patient, CFO, Council, Therapy, Research and Development Council of New Jersey, NYSE, Biology, Pharmaceutical industry, Chimera, Biochemistry, Research

Ms. Drapkin will join the company’s audit and compensation committees and Dr. Dylla will join the compensation committee.

Key Points: 
  • Ms. Drapkin will join the company’s audit and compensation committees and Dr. Dylla will join the compensation committee.
  • Ms. Drapkin served as a member of Yumanity Therapeutics, Inc.’s board of directors since the completion of the merger of Proteostasis Therapeutics, Inc. and Yumanity, Inc. and previously served on the board of directors of Proteostasis.
  • Scott Dylla, Ph.D. is currently an entrepreneur, investor and advisor of early-stage biotech companies.
  • Dr. Dylla currently serves as the chairman of the board of Chimera Bioengineering and as a board member of 3D Bio Holdings LLC.

SIRTLab Corporation Appoints Michael G. Kauffman, MD, PhD, as Co-Chairman of the Board of Directors and Chief Medical Officer

Retrieved on: 
Wednesday, June 22, 2022
Doctor of Philosophy, Harvard University, Liver disease, Internal medicine, Carfilzomib, Rheumatology, Institute of Liver and Biliary Sciences, Inflammation, Harvard Medical School, Technology, Johns Hopkins School of Medicine, Chief Medical Officers (United Kingdom), Glucose, Lipid metabolism, Epix Pharmaceuticals, Director, CEO, Takeda Oncology, Research, Gene expression, Chronic liver disease, Beth Israel Hospital, Company, Sirtuin 6, Biotechnology, SIRT6, Lipid, Metabolic syndrome, Massachusetts General Hospital, Bar-Ilan University, MD, Fatty liver disease, CMO, Research and development, NASH, Patient, Board, Longevity, NF-κB, Multimedia, The Co Founder, Mouse, Liver, Glycolysis, Management, Pharmaceutical industry, Biogen

Dr. Kauffman joins Boaz Misholi, Founder and Co-Chairman; Professor Haim Cohen, Founder and Chief Scientist; Hagit Ashush, PhD, Vice President, Research and Development; and Amir Shukrun, Chief Financial Officer.

Key Points: 
  • Dr. Kauffman joins Boaz Misholi, Founder and Co-Chairman; Professor Haim Cohen, Founder and Chief Scientist; Hagit Ashush, PhD, Vice President, Research and Development; and Amir Shukrun, Chief Financial Officer.
  • Dr. Kauffman's appointment follows positive proof of concept preclinical data in non-alcoholic steatohepatitis (NASH) and longevity models.
  • SIRT6 suppresses triglyceride synthesis, fat metabolism and inflammation (by suppression of NF-kB and other pathways), as well as glycolysis.
  • SIRTLab Corporation is a privately held liver diseases and longevity company headquartered in the Rehovot Science Park, Israel.

SIRTLab Corporation Appoints Michael G. Kauffman, MD, PhD, as Co-Chairman of the Board of Directors and Chief Medical Officer

Retrieved on: 
Wednesday, June 22, 2022
Doctor of Philosophy, Harvard University, Liver disease, Internal medicine, Carfilzomib, Rheumatology, Institute of Liver and Biliary Sciences, Inflammation, Harvard Medical School, Technology, Johns Hopkins School of Medicine, Chief Medical Officers (United Kingdom), Glucose, Lipid metabolism, Epix Pharmaceuticals, Director, CEO, Takeda Oncology, Research, Gene expression, Chronic liver disease, Beth Israel Hospital, Company, Sirtuin 6, Biotechnology, SIRT6, Lipid, Metabolic syndrome, Massachusetts General Hospital, Bar-Ilan University, MD, Fatty liver disease, CMO, Research and development, NASH, Patient, Board, Longevity, NF-κB, The Co Founder, Mouse, Liver, Glycolysis, Pharmaceutical industry, Biogen

Dr. Kauffman joins Boaz Misholi, Founder and Co-Chairman; Professor Haim Cohen, Founder and Chief Scientist; Hagit Ashush, PhD, Vice President, Research and Development; and Amir Shukrun, Chief Financial Officer.

Key Points: 
  • Dr. Kauffman joins Boaz Misholi, Founder and Co-Chairman; Professor Haim Cohen, Founder and Chief Scientist; Hagit Ashush, PhD, Vice President, Research and Development; and Amir Shukrun, Chief Financial Officer.
  • Dr. Kauffman's appointment follows positive proof of concept preclinical data in non-alcoholic steatohepatitis (NASH) and longevity models.
  • SIRT6 suppresses triglyceride synthesis, fat metabolism and inflammation (by suppression of NF-kB and other pathways), as well as glycolysis.
  • SIRTLab Corporation is a privately held liver diseases and longevity company headquartered in the Rehovot Science Park, Israel.

Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer

Retrieved on: 
Wednesday, June 15, 2022
Biotechnology, Pharmaceutical, Health, Doctor of Philosophy, R, Endocytosis, Biophysics, CEO, AMAG Pharmaceuticals, ATACS, Inotek Pharmaceuticals, Pharmacokinetics, Biomedical engineering, Proteome, Epix Pharmaceuticals, LinkedIn, Growth, Protein, Duke University, University, NASDAQ, Anatomical terms of motion, Twitter, Patient, Biomedicine, University of California, San Diego, Multimedia, ATAC, Therapy, Engineering, Sale, Fine chemical

Avilar Therapeutics , a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer.

Key Points: 
  • Avilar Therapeutics , a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer.
  • In his role at Avilar, Dr. Muzikant will be responsible for corporate and business development as well as various business operations functions.
  • View the full release here: https://www.businesswire.com/news/home/20220615005091/en/
    We are excited to welcome Adam to the Avilar leadership team during this time of significant growth of our company, said Daniel Grau, CEO and President of Avilar Therapeutics.
  • Dr. Muzikant joins Avilar after serving as Chief Business Officer of Flexion Therapeutics (NASDAQ: FLXN), where he was instrumental in the sale of the company to Pacira BioSciences for up to $1B in enterprise value.

Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors

Retrieved on: 
Thursday, November 18, 2021
Patient, Private Securities Litigation Reform Act, CAR, Risk, Industry, Johns Hopkins School of Medicine, Form, Cancer, SEC, Internal medicine, COVID-19, Annual report, Gene editing, Nasdaq, GLOBE, Board of directors, Board, Takeda Oncology, Epix Pharmaceuticals, ACET, Verastem Oncology, Form 10-K, Pharmaceutical industry, Vaccine

"Dr. Kauffman is an industry veteran with considerable experience in oncology drug development and, notably, has been instrumental in the approval of several oncology drugs.

Key Points: 
  • "Dr. Kauffman is an industry veteran with considerable experience in oncology drug development and, notably, has been instrumental in the approval of several oncology drugs.
  • Dr. Kauffman joins the Adicet board with over 20 years of experience in the life sciences industry, including expertise in preclinical research, clinical development and regulatory strategy.
  • Prior to joining Karyopharm, Dr. Kauffman was Chief Medical Officer of Onyx Pharmaceuticals Inc., which acquired Proteolix Inc.
  • Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases.